Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
The defining idea of 2025 was execution at scale—more patients pulled into…
Oncology Today—December 15, 2025
This week’s oncology update spotlights key developments, regulatory milestones,…
Oncology Today—December 1, 2025
This week’s oncology update highlights major regulatory milestones, late-stage…
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+
Lucid Diligence Brief: Phrontline Biopharma $60m Pre-A+ Professional audiences…
Cell and Gene Therapy Today—November 27, 2025
This week's Cell and Gene therapy update covers major regulatory approvals,…
Lucid Diligence Brief: NEOK Bio $75M Series A
Lucid Diligence Brief: NEOK Bio $75M Series A Professional audiences only. Not…
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC Professional…
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
Lucid Diligence Brief: Takeda and Innovent global oncology partnership…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
AACR 2025 Preview: Key Cancer Research Highlights to Watch
AACR 2025 at a glance As AACR 2025 nears, LucidQuest spotlights the…